Japanese firms Chugai Pharmaceutical and Towa Pharmaceutical have announced that Chugai has obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for osteoporosis treatment- Edirol Tablets 0.5 µg/0.75 µg (generic name: eldecalcitol, hereafter, Edirol Tablet).
Chugai Pharmaceutical Co., Ltd. announced today that it has filed a patent infringement lawsuit with the Tokyo District Court and has also filed a petition for provisional disposition order, demanding the suspension of manufacturing and distribution of the generic drugs of an osteoporosis agent, active vitamin D3 derivative Edirol® Capsule 0.5µg / 0.75µg (generic name: eldecalcitol, hereafter, Edirol Capsule), against Sawai Pharmaceutical Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd., the marketing authorization holders of generic versions of the drug, citing such parties’ infringement of a use patent owned by Chugai and Taisho Pharmaceutical Co., Ltd.